See, generally, BeckermanK.P.MorrisA.B.StekA., “Mode of Delivery and the Risk of Vertical Transmission of HIV-1,”N. Engl. J. Med. 341, no. 3 (1999): 205–6
2.
ConnorE.M.SperlingR.S.GelberR.KiselevP.ScottG.O'SullivanM.J., “Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group,”N. Engl. J. Med. 331, no. 18 (1994): 1994–1173
3.
GuayL.A.MusokeP.FlemingT.BagendaD.AllenM.NakabiitoC., “Intrapartum and Neonatal Single-Dose Nevirapine Compared with Zidovudine for Prevention of Mother-to-Child Transmission of HIV-1 in Kampala, Uganda: HIVNET 012 Randomized Trial,”Lancet351, no. 9181 (1999): 1999–795
4.
McGowanJ.P.CraneM.WizniaA.A.BlumS., “Combination Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Pregnant Women,”Obstetrics & Gynecology94, no. 5 (1999): 1999–641
5.
MofensonL.M.LambertJ.S.StiehmE.R.BethelJ.MeyerW.A.IIIWhitehouseJ., “Risk Factors for Perinatal Transmission of Human Immunodeficiency Virus Type 1 in Women Treated with Zidovudine,”N. Engl. J. Med. 341, no. 6 (1999): 1999–385
6.
WadeN.A.BirkheadG.S.WarrenB.L.CharbonneauT.T.FrenchP.T.WangL., “Abbreviated Regimens of Zidovudine Prophylaxis and Perinatal Transmission of the Human Immunodeficiency Virus,”N. Engl. J. Med. 339, no. 20 (1998):1409–14.
7.
U.S. Department of Health and Human Services Centers for Disease Control and Prevention, “Revised Guidelines for HIV Counseling, Testing and Referral and Revised Recommendations for HIV Screening of Pregnant Women,”Morbidity Mortality Weekly Reportsno. RR-19 (2001): 59–86, at 65–71.
8.
StotoM.A.AlmarioD.A.McCormickM.C., eds., Reducing the Odds: Preventing Perinatal Transmission of HIV in the United States (Washington, D.C.: National Academy Press, 1999).
9.
American Academy of Pediatrics.American College of Obstetricians and Gynecologists, “Joint Statement of the American Academy of Pediatrics and the American College of Obstetricians and Gynecologists,”Pediatrics104, no. 1 pt 1 (1999): At 128.
10.
U.S. Department of Health and Human Services Centers for Disease Control and Prevention, supra note 2, at 75–77.
11.
Centers for Disease Control and Prevention, “Advancing HIV Prevention: New Strategies for a Changing Epidemic – United States2003, Morbidity Mortality Weekly Report, 52, no. 15 (2003): 329–332, at 332.
12.
See, U.S. Department of Health and Human Services Centers for Disease Control and Prevention, supra note 2, at 71–72
13.
WatsonA., Reducing Perinatal Transmission, Health Policy Tracking Service, at <http://stateserv.hpts.org/hpts2000/issueb2000.nsf/970e745f9e50ddca852564f0007b3abd> (last visited 6/16/2000). 2003 Ind. House Enrolled Act 1630, sections 6–11 (2003) (effective 7/1/2003). N.M. Stat. Ann. § 24–2B-5 (2003) (effective 6/30/2003). Washington Administrative Code § 246-100-208 (2003) (effective 7/6/2002).
14.
N.M. Stat. Ann., supra note 7.
15.
See BayerR., Private Acts, Social Consequences: AIDS and the Politics of Public Health (New York: Free Press, 1989): At 101–136.
16.
StotoM.A.AlmarioD.A.McCormickM.C., supra note 3, at 74–85 & 104–110.
17.
Id. At 74–84 (and references therein).
18.
RoomeAHadlerJ.BirkheadG.KingS.ArchibaldC.SchragS.LanskyA.SansomS.FowlerM.OnoradoI.AndersonJ., “HIV Testing Among Pregnant Women — United States and Canada, 1998–2001,”Morbidity Mortality Weekly Report51, no. 45 (2002): 1013–1016.
19.
See generally, FadenR.R.KassN.E.PowersM., “Warrants for Screening Programs: Public, Health, Legal, and Ethical Frameworks,” in FadenR.R.GellerG.PowersM., eds., AIDS, Women, and the Next Generation: Towards a Morally Acceptable Public Policy for HIV Testing of Pregnant Women and Newborns (New York: Oxford University Press, 1991): At 1991–3
20.
GostinL.O., “Immunization, Testing, and Screening: Bodily Integrity,” in Public Health Law: Power, Duty, Restraint (Berkeley: University of California Press, (2000): 175–201.
21.
StotoM.A.AlmarioD.A.McCormickM.C., supra note 3, at 22–25, 85–96, & 113.
22.
FadenR.R.KassN.E.PowersM., supra note 13
23.
GostinL.O., supra note13
24.
StotoM.A.AlmarioD.A.McCormickM.C., supra note 3, at 24.
25.
StotoM.A.AlmarioD.A.McCormickM.C., supra note 3, at 22–25, 85–96, & 113.
26.
StotoM.A.AlmarioD.A.McCormickM.C., supra note 3, at 74–84
27.
RoomeA., supra note 12.
28.
See generally, GostinL.O.FeldblumC.WebberD.W., “Disability Discrimination in America: HIV/AIDS and Other Health Conditions,”JAMA281, no. 8 (1999):745–52
29.
“Girl Says Store Fired her Because She's HIV Positive,”The Seattle Times, Sept. 3, 2001, at Sect. A4
30.
“EEOC Raps Hospital”AIDS Policy and Law13, no. 2 (1998): At 12
31.
Bragdon v. Abbott, 524 U.S. 624 (1998)
32.
“Study Demonstrates that AIDS Stigma Remains Potent,”AIDS Policy and Law15, no.22 (2000): At 5.
33.
See generally, RothenbergK.H.PaskeyS.J.ReulandM.M.ZimmermanS.I.NorthR.L., “Domestic Violence and Partner Notification: Implications for Treatment and Counseling of Women with Hrv,”Journal of the American Medical Women's Association50, no. 3–4 (1995); 87–93
34.
RothenbergK.PaskeyS., “The Risk of Domestic Violence and Women with HIV Infection: Implications for Partner Notification, Public Policy, and the Law,”American Journal of Public Health85, no. 11 (1995): At 1995–1569
35.
MamanS.CambellJ.SweatM.GielenA., “The Intersections of HIV and Violence: Directions for Future Research and Interventions,”Social Science & Medicine50, no. 459–78(2000): At 474–5
36.
HeltonA.McFarlaneJ.AndersonE., “Battered and Pregnant: A Prevalence Study,”American Journal of Public Health77, no. 10 (1987): At 1987–1337
37.
ZierlerS.CunninghamW., “Violence Victimization after HIV Infection in a US Probability Sample of Adult Patients in Primary Care,”American Journal of Public Health90, no. 2 (2000): At 2000–208
38.
NorthR.L.RothenbergK.H.“Partner Notification and the Thereat of Domestic Violence Against Women with HFV Infection,”N. Engl. J. Med. 329, no. 16 (1993): At 1993–1194
39.
GielenA.O'CampoP.FadenR.EkeA., “Women's Disclosure of HIV Status: Experiences of Mistreatment and Violence in an Urban Setting,”Women & Health25, no. 3 (1997): At 19–31.
40.
See NorthR.L.RothenbergK.H., supra note 19
41.
GielenA.O'CampoP.FadenR.EkeA., supra note 19.
42.
See LawlessS.KippaxS.CrawfordJ., “Dirty, Diseased and Undeserving: The Positioning of HIV Positive Women,” Social Science and Medicine43, no. 9 (1996): At 1996–1371
43.
NapravnikS.RoyceR.WalterE.LimW., “HIV-1 Infected Women and Prenatal Care Utilization: Barriers and Facilitators,”AIDS Patient Care and STDs14, no. 8(2000): At 411–20
44.
OlivaG.RienksJ.McDermidM., “What High-Risk Women are Telling us about Access to Primary and Reproductive Health Care and HIV Prevention Services,”AIDS Education and Prevention11, no. 6 (1999): At 513–24.
45.
LawlessS.KippaxS.CrawfordJ., supra note 21, at 1374.
46.
See, e.g., Term. Code Ann. § 68-5-703 (2003)
47.
Tex. Health & Safety Code § 81.090 (2003)
48.
Ark. Stat. Ann. § 20-16-507 (2003)
49.
U.S. Department of Health and Human Services Centers for Disease Control and Prevention, supra note 2, at 75. Also see, N.M. Stat. Ann., supra note 7.
See GostinL.O.FeldblumC.WebberD.W., supra note 18.
76.
StatN.M.Ann, supra note 7.
77.
See generally GostinL.O., Power, Duty, Restraint (Berkeley: University of California Press: 2000)
78.
GostinL. O., “Public Health Law in a New Century: Part I: Law as a Tool to Advance the Community's Health,”JAMA283, no. 21 (2000): At 2837–41
79.
GostinL.O., “Public Health Law in a New Century: Part II: Public Health Powers and Limits,”JAMA283, no. 22 (2000): At 2000–2979
80.
GostinL.O., “Public Health Law in a New Century: Part III: Public Health Regulations: A Systematic Evaluation,”JAMA283, no. 23 (2000): At 3118–22.
81.
KleinS.BirkheadG.WrightG., supra note 26.
82.
See, e.g., NY CLS Pub Health § 2781(3) (2003) (“information about discrimination problems that disclosure of test result could cause”) and COMAR 10.18.08.06(b)(3)(l) (2003) (“That an individual with a positive HIV test result could experience: (i) Emotional discomfort; and (ii) If the test result becomes known in the community, discrimination in work, personal relationships, and insurance”).
83.
See McCulloughL.B.ChervenakFA, “General Strategies for Preventing Ethical Conflict and Crisis in Clinical Practices” in Ethics in Obstetrics and Gynecology, (New York: Oxford University Press, 1994), at 133–165 and 198–200
84.
LoB., “Ethical Issues in Obstetrics and Gynecology,” in Resolving Ethical Dilemmas: A Guide for Clinicians (Philadelphia: Lippincott, Williams & Wilkins 2000), at 302–309.
85.
See generally U.S. Department of Health and Human Services Centers for Disease Control and Prevention, supra note 2
86.
RothenbergK.H.PaskeyS.J.ReulandM.M.ZimmermanS.I.NorthR.L., supra note 19
87.
StotoM.A.AlmarioD.A.McCormickM.C., supra note 3
88.
GostinL.O., supra note 13
89.
MamanS.CampbellJ.SweateM.GielenA., supra19
90.
NorthR.L.RothenbergK.H., supra note 19.
91.
See generally LawlessS.KippaxS.CrawfordJ., supra note 21
92.
NapravnikS.RoyceR.WalterE.LimW., supra note 21
93.
OlivaG.RienksJ.McDermidM.supra note 21
94.
Ferguson v. Charleston, 121S. Ct. 1281 (2001)
95.
RobertsD., “Punishing Drug Addicts who have Babies: Women of Color, Equality, and the Right of Privacy,”Harvard Law Review104, no. 7 ((1991): 1419–82.
96.
Md. HEALTH-GENERAL Code Ann, supra note 33.
97.
StotoM.A.AlmarioD.A.McCormickM.C., supra note 3, at 110–111.
98.
SenguptaSohini, personal communication regarding unpublished research results.
99.
Bragdon v. Abbott, supra note 18.
100.
Lesley v. Chie, 250 F.3d 47 (2001), at 53.
101.
Id., at 51.
102.
See, e.g., GostinL.O.FeldblumC.WebberD.W., supra18
103.
Bragdon v. Abbott, supra note 18.
104.
See, e.g., Dept. of Social Sews. v. Carraher (In re John T.) 538 N.W.2d 761, (1995) 762 & 765–766
105.
Doe v. Div. of Youth & Family Servs., 148 F.Supp.2d 462, (2001) at 472–473.
106.
Md. HEALTH-GENERAL Code Ann, supra note 33.
107.
See generally RothenbergK.H.PaskeyS.J.ReulandM.M.ZimmermanS.I.NorthR.L., supra note 19
108.
RothenbergK.PaskeyS., supra note 19
109.
HeltonA.McFarlaneJ.AndersonE., supra note 19
110.
KleinS.BirkheadG.WrightG., supra note 26.
111.
42 USCS § 300ff-27a (2002).
112.
See, e.g., Cal. Health & Safety Code § 121015 (2004)
113.
O.C.G.A. § 24-9-47 (2003)
114.
H.R.S. § 325.101 (2003)
115.
and Md. Health & General Code Ann. § 18–337 (2003).